Longboard Pharmaceuticals, Inc. (LBPH)
Dec 2, 2024 - LBPH was delisted (reason: acquired by Lundbeck)
59.98
0.00 (0.00%)
Inactive · Last trade price
on Nov 29, 2024
Company Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases.
The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020.
Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Longboard Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Mar 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Kevin Lind |
Contact Details
Address: 4275 Executive Square, Suite 950 La Jolla, California 92037 United States | |
| Phone | 858 789 9283 |
| Website | longboardpharma.com |
Stock Details
| Ticker Symbol | LBPH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001832168 |
| CUSIP Number | 54300N103 |
| ISIN Number | US54300N1037 |
| Employer ID | 84-5009619 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin R. Lind | President, Chief Executive Officer, Secretary and Director |
| Brandi L. Roberts CPA, M.B.A. | Executive Vice President and Chief Financial Officer |
| Dr. Randall E. Kaye M.D. | Executive Vice President and Chief Medical Officer |
| Chadwick J. Orevillo MPH | Executive Vice President and Head of Operations |
| Steven W. Spector J.D. | Executive Vice President, Head of Business Development and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2024 | RW | Filing |
| Dec 2, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 2, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 2, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 2, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Dec 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Dec 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Dec 2, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 25-NSE | Filing |